Table of Contents
Breaking Advances
From the Editor's Chair
- From the Editor's ChairGeorge C. PrendergastCancer Res January 1 2015 75 (1) 3-4; DOI:10.1158/0008-5472.CAN-14-3532
Reviews
- ReviewsAmani Makkouk and George J. WeinerCancer Res January 1 2015 75 (1) 5-10; DOI:10.1158/0008-5472.CAN-14-2538
- ReviewsMaria V. Bogachek, James P. De Andrade and Ronald J. WeigelCancer Res January 1 2015 75 (1) 11-15; DOI:10.1158/0008-5472.CAN-14-2824
Priority Report
- Priority ReportNicole M. Warrington, Tao Sun, Jingqin Luo, Robert C. McKinstry, Patricia C. Parkin, Sara Ganzhorn, Debra Spoljaric, Anne C. Albers, Amanda Merkelson, Douglas R. Stewart, David A. Stevenson, David Viskochil, Todd E. Druley, Jason T. Forys, Karlyne M. Reilly, Michael J. Fisher, Uri Tabori, Jeffrey C. Allen, Joshua D. Schiffman, David H. Gutmann and Joshua B. RubinCancer Res January 1 2015 75 (1) 16-21; DOI:10.1158/0008-5472.CAN-14-1891
These results establishing a sex-specific role for cAMP regulation in affecting the risk of gliomas in NF1 patients may offer new rational strategies to reduce risk or treat brain tumors in this population.
Clinical Studies
- Clinical StudiesEvanthia Galanis, Pamela J. Atherton, Matthew J. Maurer, Keith L. Knutson, Sean C. Dowdy, William A. Cliby, Paul Haluska Jr, Harry J. Long, Ann Oberg, Ileana Aderca, Matthew S. Block, Jamie Bakkum-Gamez, Mark J. Federspiel, Stephen J. Russell, Kimberly R. Kalli, Gary Keeney, Kah Whye Peng and Lynn C. HartmannCancer Res January 1 2015 75 (1) 22-30; DOI:10.1158/0008-5472.CAN-14-2533
Although clinical application of oncolytic viruses as experimental therapies has frequently been challenged on the grounds of efficacy, more recently engineered vectors based on measles virus may offer effective options to treat certain advanced cancers such as metastatic ovarian cancer.
Integrated Systems and Technologies
- Integrated Systems and TechnologiesJakob Unger, Jörg Lohscheller, Maximilian Reiter, Katharina Eder, Christian S. Betz and Maria SchusterCancer Res January 1 2015 75 (1) 31-39; DOI:10.1158/0008-5472.CAN-14-1458
This study offers a proof of concept for a procedure to diagnose most types of laryngeal cancers, possibly helping avoid current invasive diagnostic procedures that are associated with greater time, morbidity, and cost.
Microenvironment and Immunology
- Microenvironment and Immunology | AuthorChoiceThuy L. Phung, Wa Du, Qi Xue, Sriram Ayyaswamy, Damien Gerald, Zeus Antonello, Sokha Nhek, Carole A. Perruzzi, Isabel Acevedo, Rajesh Ramanna-Valmiki, Paul Rodriguez-Waitkus, Ladan Enayati, Marcelo L. Hochman, Dina Lev, Sandaruwan Geeganage and Laura E. BenjaminCancer Res January 1 2015 75 (1) 40-50; DOI:10.1158/0008-5472.CAN-13-2961
These findings offer a preclinical proof of concept for the therapeutic utility of treating poorly understood vascular tumors such as angiosarcoma with S6K inhibitors.
- Microenvironment and Immunology | AuthorChoiceDeepak K. Kadayakkara, Michael J. Korrer, Jeff W.M. Bulte and Hyam I. LevitskyCancer Res January 1 2015 75 (1) 51-61; DOI:10.1158/0008-5472.CAN-14-0820
An adjuvant molecule that enhances the therapeutic effects of a cancer vaccine was found paradoxically to reduce the efficiency of antigen delivery to lymph nodes, challenging what has been thought to be necessary in an effective adjuvant–at least as formed by expectations from studies of infectious disease vaccines.
Molecular and Cellular Pathobiology
- Molecular and Cellular PathobiologyTaku Ito-Kureha, Naohiko Koshikawa, Mizuki Yamamoto, Kentaro Semba, Noritaka Yamaguchi, Tadashi Yamamoto, Motoharu Seiki and Jun-ichiro InoueCancer Res January 1 2015 75 (1) 62-72; DOI:10.1158/0008-5472.CAN-13-3455
These findings highlight a novel mechanistic linkage to help explain the NF-κB–dependent malignant phenotype of triple-negative breast cancer, with implications for defining useful theranostic targets in this aggressive disease.
- Molecular and Cellular PathobiologyKeun-Woo Lee, So-Young Yeo, Chang Ohk Sung and Seok-Hyung KimCancer Res January 1 2015 75 (1) 73-85; DOI:10.1158/0008-5472.CAN-14-0350
Already known as a central contributor to EMT, which drives metastatic progression in cancer cells, the transcription factor Twist1 is also found to function in cancer-associated fibroblasts, where it appears to offer a compelling target to deprogram the tumor-supporting features of the cancer microenvironment.
- Molecular and Cellular PathobiologyXiaoyu Fan, Chunyan He, Wei Jing, Xuyu Zhou, Rui Chen, Lei Cao, Minhui Zhu, Rongjie Jia, Hao Wang, Yajun Guo and Jian ZhaoCancer Res January 1 2015 75 (1) 86-97; DOI:10.1158/0008-5472.CAN-14-0615
Osteopontin is known to act in the tumor microenvironment to promote inflammatory processes that facilitate progression, but this study reveals that it also acts within macrophages that infiltrate budding liver tumors to achieve this end by altering Toll-like receptor signaling.
- Molecular and Cellular PathobiologyVerena Thalhammer, Laura A. Lopez-Garcia, David Herrero-Martin, Regina Hecker, Dominik Laubscher, Maria E. Gierisch, Marco Wachtel, Peter Bode, Paolo Nanni, Bernd Blank, Ewa Koscielniak and Beat W. SchäferCancer Res January 1 2015 75 (1) 98-110; DOI:10.1158/0008-5472.CAN-14-1246
These findings offer a preclinical proof of concept to target the mitotic kinase PLK1 as a rational strategy to treat an aggressive pediatric tumor.
- Molecular and Cellular PathobiologyTiansuo Zhao, He Ren, Jing Li, Jing Chen, Huan Zhang, Wen Xin, Yan Sun, Lei Sun, Yongwei Yang, Junwei Sun, Xiuchao Wang, Song Gao, Chongbiao Huang, Huafeng Zhang, Shengyu Yang and Jihui HaoCancer Res January 1 2015 75 (1) 111-119; DOI:10.1158/0008-5472.CAN-14-2040
This study identifies a key mediator of metastasis in pancreatic ductal carcinomas that are typically already disseminated at the time of diagnosis, a central challenge in the management of this disease.
Therapeutics, Targets, and Chemical Biology
- Therapeutics, Targets, and Chemical BiologyMatteo Curtarello, Elisabetta Zulato, Giorgia Nardo, Silvia Valtorta, Giulia Guzzo, Elisabetta Rossi, Giovanni Esposito, Aichi Msaki, Anna Pastò, Andrea Rasola, Luca Persano, Francesco Ciccarese, Roberta Bertorelle, Sergio Todde, Mario Plebani, Henrike Schroer, Stefan Walenta, Wolfgang Mueller-Klieser, Alberto Amadori, Rosa Maria Moresco and Stefano IndraccoloCancer Res January 1 2015 75 (1) 120-133; DOI:10.1158/0008-5472.CAN-13-2037
These findings suggest that the application of antiangiogenic therapy in cancer selects for metabolic traits of tumors that not only confer treatment resistance but also potentially have a more aggressive character, challenging a central tenet of antiangiogenic therapy as inherently less susceptible to the evolution of resistance.
- Therapeutics, Targets, and Chemical BiologyClaudia C. Faria, Brian J. Golbourn, Adrian M. Dubuc, Marc Remke, Roberto J. Diaz, Sameer Agnihotri, Amanda Luck, Nesrin Sabha, Samantha Olsen, Xiaochong Wu, Livia Garzia, Vijay Ramaswamy, Stephen C. Mack, Xin Wang, Michael Leadley, Denis Reynaud, Leonardo Ermini, Martin Post, Paul A. Northcott, Stefan M. Pfister, Sidney E. Croul, Marcel Kool, Andrey Korshunov, Christian A. Smith, Michael D. Taylor and James T. RutkaCancer Res January 1 2015 75 (1) 134-146; DOI:10.1158/0008-5472.CAN-13-3629
These findings provide a strong rationale to clinically evaluate foretinib immediately as a therapy for a defined subset of patients with the most common form of malignant pediatric brain tumor.
- Therapeutics, Targets, and Chemical BiologyZhi Shi, Hae R. Park, Yuhong Du, Zijian Li, Kejun Cheng, Shi-Yong Sun, Zenggang Li, Haian Fu and Fadlo R. KhuriCancer Res January 1 2015 75 (1) 147-158; DOI:10.1158/0008-5472.CAN-14-0036
The novel regulatory interface described in this report may offer a new strategy for the development of AKT inhibitors for cancer intervention.
- Therapeutics, Targets, and Chemical BiologyShi Hu, Wenyan Fu, Weihao Xu, Yang Yang, Melissa Cruz, Sandra D. Berezov, Daniel Jorissen, Hiroaki Takeda and Wangdong ZhuCancer Res January 1 2015 75 (1) 159-170; DOI:10.1158/0008-5472.CAN-14-1670
These results establish a new principle to achieve combined HER receptor inhibition and limit drug resistance using a single antibody.
- Therapeutics, Targets, and Chemical Biology | AuthorChoiceIbtissam Marchiq, Renaud Le Floch, Danièle Roux, Marie-Pierre Simon and Jacques PouyssegurCancer Res January 1 2015 75 (1) 171-180; DOI:10.1158/0008-5472.CAN-14-2260
This study offers preclinical proof of concept for targeting lactic acid export as a therapeutic approach, the effect of which can be magnified by coupling it with phenformin, an antidiabetic biguanide drug.
- Therapeutics, Targets, and Chemical BiologyAnna E. Vilgelm, Jeff S. Pawlikowski, Yan Liu, Oriana E. Hawkins, Tyler A. Davis, Jessica Smith, Kevin P. Weller, Linda W. Horton, Colt M. McClain, Gregory D. Ayers, David C. Turner, David C. Essaka, Clinton F. Stewart, Jeffrey A. Sosman, Mark C. Kelley, Jeffrey A. Ecsedy, Jeffrey N. Johnston and Ann RichmondCancer Res January 1 2015 75 (1) 181-193; DOI:10.1158/0008-5472.CAN-14-2405
These findings offer preclinical proof of concept for a combination drug treatment that leverages both senescence and immune surveillance to improve therapeutic outcomes.
Tumor and Stem Cell Biology
- Tumor and Stem Cell Biology | AuthorChoiceSara G.M. Piccirillo, Inmaculada Spiteri, Andrea Sottoriva, Anestis Touloumis, Suzan Ber, Stephen J. Price, Richard Heywood, Nicola-Jane Francis, Karen D. Howarth, Vincent P. Collins, Ashok R. Venkitaraman, Christina Curtis, John C. Marioni, Simon Tavaré and Colin WattsCancer Res January 1 2015 75 (1) 194-202; DOI:10.1158/0008-5472.CAN-13-3131
A particular region of the adult brain analogous to the embryonic forebrain germinal zone, which harbors various neural stem cell populations, is discovered in glioblastoma patients to harbor tumor-initiating cells, identifying this region as a target for immediate therapeutic attention by neuro-oncologists.
- Tumor and Stem Cell Biology | AuthorChoiceAmanda E. Boggs, Michele I. Vitolo, Rebecca A. Whipple, Monica S. Charpentier, Olga G. Goloubeva, Olga B. Ioffe, Kimberly C. Tuttle, Jana Slovic, Yiling Lu, Gordon B. Mills and Stuart S. MartinCancer Res January 1 2015 75 (1) 203-215; DOI:10.1158/0008-5472.CAN-13-3563
These results identify a tight correlation between acetylated α-tubulin levels and aggressive metastatic behavior in breast cancer, with potential implications for the definition of a simple prognostic biomarker in patients with basal-like breast cancers.
- Tumor and Stem Cell BiologyRicarda Herr, Martin Köhler, Hana Andrlová, Florian Weinberg, Yvonne Möller, Sebastian Halbach, Lisa Lutz, Justin Mastroianni, Martin Klose, Nicola Bittermann, Silke Kowar, Robert Zeiser, Monilola A. Olayioye, Silke Lassmann, Hauke Busch, Melanie Boerries and Tilman BrummerCancer Res January 1 2015 75 (1) 216-229; DOI:10.1158/0008-5472.CAN-13-3686
This article reveals a novel facet of BRAF and MEK inhibitors in triggering differentiation of colorectal tumors, providing a mechanistic rationale to immediately evaluate them clinically as antimetastatic agents in this setting.
- Tumor and Stem Cell BiologyVeerander P.S. Ghotra, Shuning He, Geertje van der Horst, Steffen Nijhoff, Hans de Bont, Annemarie Lekkerkerker, Richard Janssen, Guido Jenster, Geert J.L.H. van Leenders, A. Marije M. Hoogland, Esther I. Verhoef, Zuzanna Baranski, Jiangling Xiong, Bob van de Water, Gabri van der Pluijm, B. Ewa Snaar-Jagalska and Erik H.J. DanenCancer Res January 1 2015 75 (1) 230-240; DOI:10.1158/0008-5472.CAN-14-0629
These striking preclinical findings offer a mechanistic rationale to immediately reposition SYK kinase inhibitors currently in early clinical trials for evaluation in patients with metastatic prostate cancer.
Volume 75, Issue 1